Interpreting the CYP2D6 Results From the International Tamoxifen Pharmacogenetics Consortium

E-ISSN： 1532-6535|96|2|144-146

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.96, Iss.2, 2014-08, pp. : 144-146

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 5, 2013-05 ,pp. : 402-408

John Wiley & Sons Inc

Access to resources Recommend Favorite

CYP2D6 Genotype and Adjuvant Tamoxifen

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 138-140

John Wiley & Sons Inc

Access to resources Recommend Favorite

CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 141-144

John Wiley & Sons Inc

Access to resources Recommend Favorite

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 216-227

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 5, 2014-11 ,pp. : 542-548

John Wiley & Sons Inc

Access to resources Recommend Favorite